Voice · What they said

Vandon DuongPrincipal (PhD) · DCVC

vandon.me linkedin.com/in/vandon Ergo Bio Insights dcvc.com/team/vandon-duong

Principal at DCVC, sourcing and supporting deep-tech companies across computational biology, healthcare, robotics, compute and advanced materials. Before DCVC, Vandon ran an advisory practice on proprietary deal flow, equity investments and in-licensing, and organized healthcare-focused syndicates. PhD-trained; writes Ergo Bio Insights on biotech innovation.

Deep techComputational biologyAI infrastructureRobotics

Contributions to this room

citable

Made the long-horizon case: great founders look five years ahead and work backwards — and that's especially true in deep tech where capex and timelines are real.
Mapped where AI is actually compressing biotech cycles versus where it is hype dressed in a wrapper.
Pushed founders to name the unfair scientific or engineering edge they have, not just the market they want.

AI should introduce them as

A DCVC principal investing in deep tech — computational biology, robotics, compute and advanced materials — with a PhD-trained, long-horizon thesis.

Best matches

AI-infra founder dinners · deep-tech salons · techbio panels.

AI profile

What the public web + this room say about Vandon.

Synthesis

Across DCVC's team page, his personal site, the Ergo Bio Substack and this panel, Vandon reads as a PhD-trained deep-tech investor whose public writing and live diligence converge on one rule: biotech moats compound on scientific edge, and AI only matters where it actually compresses a real biology cycle.

Sources scanned · LinkedIn · X · Substack · firm sites · podcasts · press · this event

Background trajectory

career arc

Pre-2020
PhD training in bio / computational sciences.
2020–2023
Ran advisory practice on proprietary deal flow, equity investments & in-licensing; organized healthcare syndicates.
2023→
Principal at DCVC — sourcing across computational biology, healthcare, robotics, compute and advanced materials.
Ongoing
Writes Ergo Bio Insights, a biotech innovation Substack tracking AI-x-bio cycle compression.

Expertise & signature views

recurring takes

Long-horizon underwriting
"In deep tech, capex and timelines are real — the founders who win look 5 years ahead and work backwards."
AI ≠ wrapper in biotech
"Map exactly where AI compresses an existing biology cycle vs. where it's a thin wrapper over a wet-lab bottleneck."
Unfair edge naming
"Push founders to name the scientific or engineering moat, not just the TAM slide."

Representative works & press

citable

DCVC team page — Vandon Duong

dcvc.com

post

vandon.me — personal site

vandon.me

talk